PBD News and Press, Invesco Global Clean Energy From 02/11/21

Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock PR Newswire CARMIEL, Israel , Feb. 11, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, produc...

Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery PR Newswire CARMIEL, Israel , Feb. 11, 2021 /PRNewswire...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021 Phase III BRIDGE open-label, switch-over clinical trial met key objectives for safety and ...

Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021 Data to be presented in an oral presentation and a poster presentation PR Newswire CARMIEL, Israel , Feb. 1, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (N...

The Russell 2000 Index closed out 2020 with a roar, surging 31.4% in the fourth quarter and posting its highest ever monthly return in November. However, while Oil, Gas and Coal delivered 50.1% for the quarter, it was far from one of the highest contributors to the Russell 2000 Index ...

SPDR S&P Kensho Clean Power ETF (CNRG) is State Street Global Advisors open ended fund offering risk exposure to in vogue alternative energy sources. Renewables such a solar, wind, and biomass make up a major part of the fund’s assets. And with best-in-class expense rat...

Here are the ETFs and ETNs with the strongest price performance going into 2021, excluding leveraged and inverse ETFs. We've listed the ETFs with the strongest three month performance, and also provided their one month performance.We've grouped the ETFs by theme. There are four themes behind ...

Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in January PR Newswire CARMIEL, Israel , Jan. 4, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development,...

Protalix BioTherapeutics Issues 2020 Letter to Shareholders PR Newswire CARMIEL, Israel , Dec. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commerc...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease Phase III BRIDGE open-label, switch-over clinical trial met key objective...